Form 4: Elanco Executive Kinard Receives Stock Options and Restricted Stock Units

David S. Kinard, an Executive Vice President at Elanco Animal Health, was granted stock options and restricted stock units on March 3, 2025.

Summary

• David S. Kinard, an Executive Vice President at Elanco Animal Health, received 46,383 stock options with an exercise price of $11.31 on March 3, 2025.
• These options vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028, and expire on March 3, 2035.
• Kinard also received 22,105 restricted stock units on the same date, which vest similarly in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028.
• Following these transactions, Kinard directly owns 188,878 shares of Elanco common stock and 46,383 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices that align management interests with shareholder value.

Positives

• The grant of stock options and restricted stock units aligns Kinard's interests with those of Elanco's shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Executive compensation packages including stock options and restricted stock units are common in the animal health industry to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Companies like Zoetis and Merck Animal Health also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry standards for executives at similar levels.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a positive sign of the company's commitment to its leadership.

Key Dates